Clene Inc Revenue Growth Rates (CLNN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Clene Inc   (NASDAQ: CLNN)
 

CLNN's Revenue Growth by Quarter and Year

Clene Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CLNN/growth
https://api.csimarket.com/api/v1/companies/CLNN/fundamentals
https://api.csimarket.com/api/v1/companies/CLNN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CLNN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.06
2nd Quarter June 0.09
1st Quarter March 0.02
FY 0.17

CLNNs Annual Revenue
Clene Inc 's Revenue in the fiscal year 2025 $ 0.20 millions
Clene Inc 's Revenue in the fiscal year 2024 $ 0.34 millions
Clene Inc 's Revenue in the fiscal year 2023 $ 0.65 millions
Clene Inc 's Revenue in the fiscal year 2022 $ 0.47 millions
Clene Inc 's Revenue in the fiscal year 2021 $ 0.72 millions




CLNN Revenue third quarter 2026 Y/Y Growth Comment
Clene Inc achieved in the third quarter 2026, above Company average Revenue surge of 180% year on year, to $ 0.06 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Revenue growth. While Clene Inc ' s Revenue doubling of 180% ranks overall at the positon no. 142 in the third quarter 2026.


CLNN Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 180 %
2nd Quarter June 200 %
1st Quarter March -75 %
FY   -

Financial Statements
Clene Inc 's third quarter 2026 Revenue $ 0.06 millions CLNN's Income Statement
Clene Inc 's third quarter 2025 Revenue $ 0.02 millions Quarterly CLNN's Income Statement


CLNN Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -37.78 %
2nd Quarter June 350 %
1st Quarter March -75 %
FY (Year on Year)   -


Back to CLNN Growth rate Comparisons >> Back to CLNN Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #44
Overall #142

Revenue Y/Y Growth Statistics
High Average Low
2133.33 % 160.63 % -85.92 %
(Dec 31 2021)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #44
Overall #142
Revenue Y/Y Growth Statistics
High Average Low
2133.33 % 160.63 % -85.92 %
(Dec 31 2021)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Clene Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
988.89 % 105.3 % -87.14 %
(Sep 30 2020)  


CLNN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Clene Inc disclosed fall in Revenue from the second quarter by -37.78% to $ 0.06 millions, from $ 0.09 millions achived in the previous reporting period.

But that's not important problem, as Clene Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Clene Inc 's Revenue growth quarter on quarter, overall rank is 60.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #24
Overall #60
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #24
Overall #60
Revenue Q/Q Growth Statistics
High Average Low
988.89 % 105.3 % -87.14 %
(Sep 30 2020)  


CLNN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Clene Inc disclosed fall in Revenue from the second quarter by -37.78% to $ 0.06 millions, from $ 0.09 millions achived in the previous reporting period.

But that's not important problem, as Clene Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Clene Inc 's Revenue growth quarter on quarter, overall rank is 60.


Clene Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.20
Y / Y Revenue Growth (TTM) -31.12 %
Year on Year Revenue Growth Overall Ranking # 3559
Seqeuential Revenue Change (TTM) 47.01 %
Seq. Revenue Growth (TTM) Overall Ranking # 3397


Cumulative Revenue growth Comment
Clene Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Clene Inc 's annual Revenue rise would be -31.12% year on year to $0 millions.

In the Healthcare sector 478 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3022 to 3559.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 149
Healthcare Sector # 479
Overall # 3559

Revenue TTM Y/Y Growth Statistics
High Average Low
250.97 %
 2.67 %
-61.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 149
Sector # 453
S&P 500 # 3397
Cumulative Revenue growth Comment
Clene Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Clene Inc 's annual Revenue drop would be -31.12% year on year to $0 millions.

In the Healthcare sector 478 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3022 to 3559.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 149
Healthcare Sector # 479
Overall # 3559

Revenue TTM Y/Y Growth Statistics
High Average Low
250.97 %
2.67 %
-61.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 149
Sector # 453
S&P 500 # 3397




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CLNN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions


About Clene Inc Revenue Growth Rates (CLNN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Clene Inc (CIK 1822791).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-034776
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Clene Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.